Both results will be judged individually as they are separate submission, there are some company who have FDA approval for their product and are selling it in the US market but have yet to received their TGA/CE approval for that same product, as the submission are treated differently. for separate market.
This medical device was developed from the Bill Gate foundation, he was never an investor in RAP, doesn't invest in stocks and is a philanthropist.
Insto have been investing in RAP and are substantial share holder who haven't significantly sold.
The shares that were held by UQ are from the commercial/business part of the university and have nothing to do with RAP's clinical trials, they are risk adverts and choose to sell high like other investors did as they already made heaps.
The market will judge the up-coming news released by management, the progress has been excellent this year with exceptional pediatric Australia double blind and independent result which will be used for TGA/CE submission, good pediatric US double blind and independent result (except for pneumonia/bronchitis) which will be used for FDA submission and up-coming result for Adult Australia BreathEasy and OSA double blind and independent which will be used for TGA/CE submission if they are good.
IMO (and Morgan's), the pps currently has been oversold likely due to those SI traders that did the CR at 22c, the pps should be at 20c, IMO.
(20min delay)